Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Prog Cardiovasc Dis ; 66: 70-79, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34332662

RESUMEN

Electrical storm is present when a cluster of ventricular arrhythmias (VAs) occurs within a short time frame. The most widely accepted definition is 3 or more episodes of VA within a 24-h period, although prognostic risk begins to rise when 2 or more events occur within 3months. Electrical storm often presents as a medical emergency in the form of recurrent implantable cardiac defibrillator (ICD) shocks, recurrent syncope in patients with no ICD or low cardiac output symptoms. Management often requires a multimodality approach including ICD management, pharmacologic therapy, catheter ablation and modulations of the autonomic nervous system. In this article, we review the definition, prognosis and management of electrical storm.


Asunto(s)
Antiarrítmicos/uso terapéutico , Desnervación Autonómica , Estimulación Cardíaca Artificial , Ablación por Catéter , Oxigenación por Membrana Extracorpórea , Taquicardia Ventricular/terapia , Fibrilación Ventricular/terapia , Potenciales de Acción/efectos de los fármacos , Antiarrítmicos/efectos adversos , Desnervación Autonómica/efectos adversos , Desnervación Autonómica/mortalidad , Estimulación Cardíaca Artificial/efectos adversos , Estimulación Cardíaca Artificial/mortalidad , Ablación por Catéter/efectos adversos , Ablación por Catéter/mortalidad , Toma de Decisiones Clínicas , Técnicas de Apoyo para la Decisión , Oxigenación por Membrana Extracorpórea/efectos adversos , Oxigenación por Membrana Extracorpórea/mortalidad , Sistema de Conducción Cardíaco/efectos de los fármacos , Sistema de Conducción Cardíaco/fisiopatología , Sistema de Conducción Cardíaco/cirugía , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Marcapaso Artificial , Recurrencia , Medición de Riesgo , Factores de Riesgo , Taquicardia Ventricular/diagnóstico , Taquicardia Ventricular/mortalidad , Taquicardia Ventricular/fisiopatología , Resultado del Tratamiento , Fibrilación Ventricular/diagnóstico , Fibrilación Ventricular/mortalidad , Fibrilación Ventricular/fisiopatología
2.
Catheter Cardiovasc Interv ; 94(4): 644-650, 2019 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-31334914

RESUMEN

INTRODUCTION: Chagas disease is one of the most relevant endemic parasitic diseases in Latin America, affecting approximately 6 million people. Overt Chagas heart disease is an ominous condition, occurring in 20-30% of infected individuals, which has besides the persistent myocarditis a peculiar intracardiac ganglionic neuronal depletion and dysautonomy. This study aims to evaluate the safety and feasibility of renal denervation for patients with advanced symptomatic Chagas cardiomyopathy. METHODS: Open-label prospective pilot study that randomized patients with Chagas heart disease to either renal denervation or conservative treatment (2:1 ratio). The primary endpoint was the incidence of major adverse events at 9 months, defined as a composite of all-cause death, myocardial infarction, stroke, need for renal artery invasive treatment, or worsening renal function. RESULTS: A total of 17 patients were allocated for renal denervation (n = 11) or conservative treatment (n = 6). Included patients had severe symptomatic heart disease, with markedly depressed left ventricular function (average ejection fraction 26.7 ± 4.9%). For patients randomized to renal denervation, the procedure was performed successfully and uneventfully. After 9 months, the primary endpoint occurred in 36.4% of patients in the renal denervation group and 50.0% in the control arm (p = .6). After 9 months, clinical, laboratory, functional, echocardiographic, and quality of life parameters were similar between groups. CONCLUSIONS: This pilot study suggests that renal denervation is safe and feasible in patients with Chagas cardiomyopathy, warranting future studies to better evaluate the clinical efficacy of the interventional strategy in improving the prognosis of this high-risk population.


Asunto(s)
Desnervación Autonómica , Ablación por Catéter , Cardiomiopatía Chagásica/cirugía , Insuficiencia Cardíaca/cirugía , Riñón/inervación , Anciano , Desnervación Autonómica/efectos adversos , Desnervación Autonómica/mortalidad , Brasil , Ablación por Catéter/efectos adversos , Ablación por Catéter/mortalidad , Cardiomiopatía Chagásica/mortalidad , Cardiomiopatía Chagásica/parasitología , Cardiomiopatía Chagásica/fisiopatología , Estudios de Factibilidad , Femenino , Insuficiencia Cardíaca/mortalidad , Insuficiencia Cardíaca/parasitología , Insuficiencia Cardíaca/fisiopatología , Humanos , Masculino , Persona de Mediana Edad , Proyectos Piloto , Estudios Prospectivos , Recuperación de la Función , Factores de Tiempo , Resultado del Tratamiento
3.
JACC Cardiovasc Interv ; 12(3): 274-284, 2019 02 11.
Artículo en Inglés | MEDLINE | ID: mdl-30732732

RESUMEN

OBJECTIVES: The authors sought to assess the benefits of pulmonary artery denervation (PADN) among combined pre- and post-capillary pulmonary hypertension (CpcPH) patients in a prospective, randomized, sham-controlled trial. BACKGROUND: PADN has been shown to improve hemodynamics of pulmonary arterial hypertension in a series of patients. Additionally, benefits of targeted medical therapy for patients with CpcPH secondary to left-sided heart failure are unknown. METHODS: Ninety-eight CpcPH patients, defined as mean pulmonary arterial pressure ≥25 mm Hg, pulmonary capillary wedge pressure >15 mm Hg, and pulmonary vascular resistance (PVR) >3.0 Wood units (WU), were randomly assigned to PADN or sildenafil plus sham PADN. Standard medical therapy for heart failure was administered to all patients in both groups. The primary endpoint was the increase in the 6-min walk distance at the 6-month follow-up. The secondary endpoint was change in PVR. Clinical worsening was assessed in a post hoc analysis. The main safety endpoint was occurrence of pulmonary embolism. RESULTS: At 6 months, the mean increases in the 6-min walk distance were 83 m in the PADN group and 15 m in the sildenafil group (least square mean difference 66 m, 95% confidence interval: 38.2 to 98.8 m; p < 0.001). PADN treatment was associated with a significantly lower PVR than in the sildenafil group (4.2 ± 1.5 WU vs. 6.1 ± 2.9 WU; p = 0.001). Clinical worsening was less frequent in the PADN group compared with the sildenafil group (16.7% vs. 40%; p = 0.014). At the end of the study, there were 7 all-cause deaths and 2 cases of pulmonary embolism. CONCLUSIONS: PADN is associated with significant improvements in hemodynamic and clinical outcomes in patients with CpcPH. Further studies are warranted to define its precise role in the treatment of this patient population. (Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure [PADN-5]; NCT02220335).


Asunto(s)
Presión Arterial , Desnervación Autonómica , Tolerancia al Ejercicio , Insuficiencia Cardíaca/fisiopatología , Hipertensión Pulmonar/cirugía , Arteria Pulmonar/inervación , Prueba de Paso , Anciano , Desnervación Autonómica/efectos adversos , Desnervación Autonómica/mortalidad , China , Femenino , Insuficiencia Cardíaca/diagnóstico , Insuficiencia Cardíaca/mortalidad , Humanos , Hipertensión Pulmonar/etiología , Hipertensión Pulmonar/mortalidad , Hipertensión Pulmonar/fisiopatología , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Estudios Prospectivos , Embolia Pulmonar/mortalidad , Embolia Pulmonar/fisiopatología , Recuperación de la Función , Factores de Riesgo , Factores de Tiempo , Resultado del Tratamiento
4.
J Interv Card Electrophysiol ; 50(3): 253-260, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28887742

RESUMEN

PURPOSE: Adjunctive ganglionated plexi (GP) ablation may improve success rates for treatment of atrial fibrillation (AF) when combined with pulmonary vein (PV) isolation. Existing meta-analyses on GP ablation have included observational studies and have not incorporated more recent randomized clinical trial data. Moreover, the impact of AF subtype (paroxysmal vs. persistent) on outcomes of GP ablation has not been well established. METHODS: We performed a meta-analysis of randomized controlled trials (RCTs) comparing GP ablation + pulmonary vein (PV) isolation versus PV isolation alone according to the subtype of AF. The primary endpoint was freedom from sustained AF or atrial tachyarrhythmia (AT) after a single procedure. RESULTS: Across four RCTs, 718 patients (358 and 360 that underwent GP ablation + PV isolation [intervention] vs. PV isolation alone [control], respectively) were included in the study. Mean left atrial size and left ventricular ejection fraction were 45.7 mm and 54.8%, respectively. Among paroxysmal AF patients, GP ablation was linked to significantly higher freedom from AT/AF (75.8 vs. 60.0% for the intervention vs. control arms respectively; OR [95% CI]: 2.22 [1.36-3.61], P = 0.001). Among persistent AF patients, GP ablation was associated with a non-significant trend towards higher rates of freedom from AT/AF (54.7 vs. 43.3% for the intervention vs. control arms respectively; OR [95% CI]: 1.55 [0.96-2.52], P = 0.08). In all cases, heterogeneity was found to be low (I 2 of 32% or lower). CONCLUSIONS: Compared to PV isolation alone, GP ablation + PV isolation is associated with better outcomes in patients with paroxysmal AF and without significant structural heart disease.


Asunto(s)
Fibrilación Atrial/cirugía , Desnervación Autonómica/métodos , Ablación por Catéter/métodos , Ganglios Autónomos/cirugía , Venas Pulmonares/cirugía , Taquicardia Paroxística/cirugía , Anciano , Fibrilación Atrial/diagnóstico por imagen , Fibrilación Atrial/mortalidad , Desnervación Autonómica/mortalidad , Ablación por Catéter/mortalidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto , Recurrencia , Medición de Riesgo , Análisis de Supervivencia , Taquicardia Paroxística/diagnóstico por imagen , Taquicardia Paroxística/mortalidad , Resultado del Tratamiento
5.
Clin Exp Pharmacol Physiol ; 37(4): 447-52, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19878213

RESUMEN

1. Impairmant of baroreflex sensitivity (BRS) has been implicated in the reduction of heart rate variability (HRV) and in the increased risk of death after myocardial infarction (MI). In the present study, we investigated whether the additional impairment in BRS induced by sinoaortic baroreceptor denervation (SAD) in MI rats is associated with changes in the low-frequency (LF) component of HRV and increased mortality rate. 2. Rats were randomly divided into four groups: control, MI, denervated (SAD) and SAD + MI rats. Left ventricular (LV) function was evaluated by echocardiography. Autonomic components were assessed by power spectral analysis and BRS. 3. Myocardial infarction (90 days) reduced ejection fraction (by approximately 42%) in both the MI and SAD + MI groups; however, an increase in LV mass and diastolic dysfunction were observed only in the SAD + MI group. Furthermore, BRS, HRV and the LF power of HRV were reduced after MI, with an exacerbated reduction seen in SAD + MI rats. The LF component of blood pressure variability (BPV) was increased in the MI, SAD and SAD + MI groups compared with the control group. Mortality was higher in the MI groups compared with the non-infarcted groups, with an additional increase in mortality in the SAD + MI group compared with the MI group. Correlations were obtained between BRS and the LF component of HRV and between LV mass and the LF component of BPV. 4. Together, the results indicate that the abolishment of BRS induced by SAD in MI rats further reduces the LF band of HRV, resulting in a worse cardiac remodelling and increased mortality in these rats. These data highlight the importance of this mechanism in the prognosis of patients after an ischaemic event.


Asunto(s)
Enfermedades del Sistema Nervioso Autónomo/mortalidad , Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Hemodinámica/fisiología , Infarto del Miocardio/mortalidad , Infarto del Miocardio/fisiopatología , Remodelación Ventricular/fisiología , Animales , Aorta/inervación , Desnervación Autonómica/efectos adversos , Desnervación Autonómica/mortalidad , Enfermedades del Sistema Nervioso Autónomo/complicaciones , Enfermedades del Sistema Nervioso Autónomo/diagnóstico , Barorreflejo/fisiología , Presión Sanguínea/fisiología , Seno Carotídeo/inervación , Frecuencia Cardíaca/fisiología , Hipertrofia Ventricular Izquierda/fisiopatología , Masculino , Infarto del Miocardio/complicaciones , Infarto del Miocardio/diagnóstico , Tamaño de los Órganos , Presorreceptores/cirugía , Pronóstico , Distribución Aleatoria , Ratas , Ratas Wistar , Factores de Riesgo , Volumen Sistólico/fisiología , Nervio Vago/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...